Dose-Weighted Adjusted Mantel-Haenszel Tests for Numeric Scaled Strata in a Randomized Trial by Gansky, Stuart A. et al.
Dose-Weighted Adjusted Mantel-Haenszel Tests for Numeric
Scaled Strata in a Randomized Trial
Stuart A. Gansky,
University of California, San Francisco
Nancy F. Cheng, and
University of California, San Francisco
Gary G. Koch
University of North Carolina at Chapel Hill
Abstract
A recent three-arm parallel groups randomized clinical prevention trial had a protocol deviation
causing participants to have fewer active doses of an in-office treatment than planned. The original
statistical analysis plan stipulated a minimal assumption randomization-based extended Mantel-
Haenszel (EMH) trend test of the high frequency, low frequency, and zero frequency treatment
groups and a binary outcome. Thus a dose-weighted adjusted EMH (DWAEMH) test was
developed with an extra set of weights corresponding to the number of active doses actually
available, in the spirit of a pattern mixture model. The method can easily be implemented using
standard statistical software. A set of Monte Carlo simulations using a logistic model was
undertaken with (and without) actual dose-response effects through 1000 replicates for empirical
power estimates (and 2100 for empirical size). Results showed size was maintained and power
was improved for DWAEMH versus EMH and logistic regression Wald tests in the presence of a
dose effect and treatment by dose interaction.
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Introduction
Mantel-Haenszel (MH) chi-square tests for sets of 2×2 tables (e.g. stratified trials with a
dichotomous treatment and dichotomous response) and their extensions for sets of r × c
tables with ordinally or nominally scaled r rows and c columns have been extensively
studied and utilized in randomized controlled clinical trials (e.g. Mantel and Haenszel 1959;
van Elteren 1960; Koch and Edwards 1988; Stokes, Davis and Koch 2000). MH and
extended MH (EMH) tests have many favorable properties, particularly being minimal
assumption methods only assuming randomization. A variety of scores for ordinal rows and/
or columns have been implemented in appropriate settings to use with EMH tests including
integer scores, rank scores, standardized midrank scores, exponential scores, and Normal
scores (e.g. Koch and Edwards 1988). However, MH and EMH tests incorporate the
stratification factor as a nominally scaled factor, weighting the individual strata by their
relative sample size to produce a weighted aggregate test of the independence of the rows
and columns. There may be situations including randomized trials in which it would be
desirable to incorporate a numerically or ordinally scaled stratification factor into the MH or
EMH trend test to produce a dose-weighted adjusted MH (DWAMH) or EMH (DWAEMH)
test. This paper describes a particular real world trial in which a dose-weighted adjusted test
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would be appropriate, proposes a DWAEMH test, provides some simulation results as well
as results from the example trial, discusses limitations and advantages of these tests, and
suggests some other settings, including randomized trials, in which this approach might be
useful.
Motivating Example: Fluoride Varnish Randomized Controlled Clinical Trial
A recent randomized controlled clinical trial (Weintraub et al. 2006) of 376 preschool aged
children with three parallel groups evaluated fluoride varnish (FV), which had not been
adequately tested in this age group, as a potential caries preventive agent. FV is a non-
invasive, inexpensive treatment that dental personnel can apply to children’s teeth in-office.
Children, caries-free and 6–44 months old at baseline, were randomly assigned in permuted
blocks to one of three arms stratifying on the two clinics: counseling only (0 FV control),
counseling plus 2 FV applications (i.e. every 12 months), and counseling plus 4 FV
applications (i.e. every 6 months). Importantly, although the dentist applying FV used the
same clinical set-up for the control group as the FV groups and dipped the applicator brush
into water to attempt to keep parents/guardians masked to treatment group assignment, the
design did not include a placebo FV group. One pediatric dentist masked to treatment group
examined children 1 and 2 years post-randomization to evaluate the number of decayed or
filled primary tooth surfaces (dfs). The primary outcome measure was caries incidence
(dfs>0). Ultimately, a total of 280 (74%) children had at least one follow-up exam. The trial
took place between October, 2000 and July, 2004. (At trial completion, the missing
completely at random (MCAR) assumption was found untenable with dropouts missing at
random (MAR) since there were baseline covariates relating to dropping out; more
importantly for ethical reasons, children with caries at the 1-year follow-up were exited from
the study as preventive intervention failures and referred for the standard of care (therapeutic
FV treatment). Interested readers are referred to another publication for further information
on MCAR testing and multiple imputation analyses for this trial (Gansky & Neuhaus 2009).)
Due to the discrete time-to-event aspect of the study, a secondary outcome measure could be
the ordinal response: no caries at either follow-up; no caries at 1 year but caries at 2 years;
and caries at 1 year. Additionally, based on this design feature, a supplemental Mantel-Cox
discrete time-to-event analysis could be performed.
A safety substudy of salivary fluoride content was also conducted in children in the 2FV and
4FV groups, collecting saliva samples at four times relative to FV application: pre-
application, 30-minute post-application, 2-hour post-application, and 1-week post-
application. Saliva samples were processed in batches to determine fluoride content. Upon
analyzing these samples, the researchers discovered that between November, 2001 and
August, 2002, the manufacturer had inadvertently shipped one lot of placebo FV intended
for another study instead of active FV. Thus, during a 10-month period of the 46-month
trial, no one received active FV for the in-office applications (Weintraub et al. online
appendix 2006). As shown in Table 1, this resulted in only 22% of the 2FV group receiving
2 active applications and 1% of the 4FV receiving 4 active applications; 78% of the 2FV
received 1 active application, while 48% of the 4FV group received 2 active applications
and 31% received 3. Understandably, the investigators, sponsor, and data and safety
monitoring board (DSMB) members were concerned that the protocol deviation would result
in the trial no longer having adequate power to detect a clinically meaningful difference
among the groups. Thus, the sample size calculation and the initial analysis plan, which
called for a minimal assumption 1 degree of freedom (df) EMH correlation test to assess the
relationship among the 3 ordinal treatment levels in caries incidence by 2 years, were re-
evaluated and a more powerful minimal assumption method was sought.
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Possible existing statistical methods, particularly those for non-compliance/non-adherence
were surveyed for applicability in this unusual scenario. An instrumental variables approach
(e.g. Greenland, 2000) was considered as a potential solution, but did not seem appropriate
as very few participants were treated as planned; even with a sufficient number of
participants with the treatment as planned, it is unclear if this method would have been
appropriate. Causal effects modeling with potential outcomes (e.g. Little & Rubin, 2000)
was evaluated, but since the source of non-compliance was temporal in nature and external
to the study (i.e. active treatment depended only on enrollment date and not through the will
of participants) groups such as defiers, never takers, and always takers did not exist. Finally,
the pattern mixture model (PMM) for randomization-based MH test method (Sato, 2001;
Matsuyama, 2002) was considered relevant for this trial.
To apply the PMM for MH, stratify participants on the eligible dosing; i.e., the number of
active applications they would have received in this trial if they were all assigned to the 4FV
(every 6 month) group as in the schematic in Figure 1. This can be determined based on
accrual date and knowledge of usage of the active and inactive lots. Of the 24=16 possible
patterns of active/inactive across the 4 treatment periods (baseline, 6 months, 12 months,
and 18 months), only 9 were actually realized: AAAA, AAAI, AAIA, AIAA, IAAA, AAII,
AIIA, IIAA, and AIII, where A=active and I=inactive application (or, for purposes of
illustrating the DWAEMH method, missed visit). Stratifying on these patterns would be akin
to the methods of Sato (2001) and Matsuyama (2002).
However, since the stratification variable is the eligible dosing (number of possible active
applications), that factor has a natural metric on the integer scale that could be used for a
dose-response type analysis (i.e. 3 for AAAI, AAIA, AIAA, and IAAA; 2 for AAII, AIIA,
and IIAA; and 1 for AIII; AAAA was categorized with those receiving 3 active since there
was only one participant in that group). Thus, in addition to the usual row and column
weights of EMH tests, adding stratum weights could account for eligible dose (possible
number of active applications).
Methods
The standard EMH chi-square statistic (QEMH) across the H strata is calculated as
where nh is the observed count vector with elements nhij defined in Figure 1, mh = nh(ph•*
⊗ ph*• is the expected count vector, ph*• and ph•* are the row and column marginal
proportion vectors, ⊗ is the left Kronecker product operator (which multiplies the matrix on
the left by the elements of the matrix on the right),
 is the covariance matrix for the h-th
stratum, Dph is a diagonal matrix with elements of vector ph on the main diagonal, and Ah is
a non-redundant linear operator matrix of row and column scores: Ah= c′h ⊗ r′h, where rh is
the vector of row scores and ch is the vector of column scores. The originally planned
standard application of QEMH to the fluoride varnish trial would define two strata (H=2) for
the clinics. Although QEMH does not require homogeneity of odds ratio across strata for its
use, it can have reduced power with heterogeneous odds ratios, particulary when stratum-
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specific effects are in opposite directions that tend to cancel each other (i.e., a certain type of
stratum by row (treatment) interaction).
The dose-weighted adjusted EMH (DWAEMH) test (QDWAEMH) would extend the standard
EMH test with a set of stratum scores, wh, augmenting the usual score matrix for a new
linear operator matrix defined as A*h=whAh=whc′h⊗r′h. Then QDWAEMH is a modification
of the EMH correlation statistic (QCSMH) with stratum scores (wh) added (Stokes, Davis and
Koch, 2000) which can be shown as:
where r ̄h and c̄h are the mean row and column scores in the h-th stratum, respectively, and is
similar in spirit to a stratum-weighted Pearson correlation coefficient between rows and
columns.
Generally with a 3-level ordinal treatment and binary response, the usual EMH test would
have score vectors rh = [0 1 2]′ and whch = [0 1]′ for all h=1, 2, … H strata, while the
DWAEMH test would have score vectors rh = [0 1 2]′ and whch = [0 wh]′ for stratum
weights wh which could involve integer, standardized midrank (modified ridit), exponential,
Normal, or other scores. In this particular example trial with binary response, the usual EMH
test would have score vectors rh = [0 1 2]′ and whch = [0 1]′ for all h=1, 2, … H (= 2 clinics
× 3 eligible dosing groups = 6) strata, while the DWAEMH test would have score vectors rh
= [0 1 2]′ and whch = [0 wh]′ where wh=1, 2, 3 according to the eligible dosing (i.e. number
of active applications which was 1, 2 or 3) within each clinic, as a natural choice. More
generally, QCSMH can have stratum scores whch varying across strata according to categories
of one or more stratification factors (such as eligible dosing groups), while remaining
constant across strata for the other stratification factor(s) (such as clinics) in the overall
cross-classification of these factors (H=6 for 2 clinics × 3 eligible dosing groups).
Simulations
A logistic model was used to simulate power for 1000 replicates under various conditions,
each with a sample size of 189 (63 per treatment group each with 21 at each of 3 doses),
which was the projected retained sample size for the motivating trial (but with a null center
effect) at the time of the power analysis for the DSMB meeting. The simulated logistic
probability (p) for the conditions was
or, equivalently,
where the intercept α=0; the treatment effect β=0.1 to 0.7 in 0.1 increments; the treatment
group for number of annual applications t=0,1,2 (corresponding to 0FV, 2FV, and 4FV,
respectively); the dose effect γ=0, 0.25, 0.50, 0.75; the number of active applications
(eligible dosing) covariate w=1,2,3; and the treatment by dose interaction Φ=0, 0.25, 0.50.
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Six combinations of (γ, Φ) were used to assess power: (0.25, 0), (0.50, 0), (0.50, 0.25),
(0.75, 0.25), (0.25, 0.25), and (0.50, 0.50). To assess size (Type I error), α=β=γ=Φ=0 was
used with 2100 replicates to provide an appropriately small standard error (yielding
confidence interval half-widths less than 0.01). For both power and size, Bernoulli random
variables were generated from the logistic probability (p) with the SAS call ranbin function
with attention to maintain unique seed values. From the prior equation for logit(p), the
contrast for the difference between t=0 and t=2 is
so for w=1, 2, 3, the equal weighted treatment effect (odds ratio) is estimated by {(−2β+2Φ)
+ (−2β) + (−2β−2Φ)}/3 = −2β, while the dose-weighted treatment effect with weights 1, 2,
3 is estimated by {(−2β+2Φ)/6 + (−4β)/6 + (−6β−6Φ)/6 = −2β−2/3Φ; for the contrast of the
difference between t=0 and t=1, the equal weighted treatment effect is estimated by −β,
while the dose-weighted treatment effect is estimated by −β−1/3Φ.
For the simulated null scenario (zero effects), QEMH and QDWAEMH were determined and the
proportion of their corresponding p-values less than or equal to 0.05 yielded empirical Type
I error estimates. Empirical Type I error estimates were determined for Wald test statistics
(QW) from a standard main effects logistic regression model with an intercept and treatment
effect (which is misspecified when Φ ≠0), which was used to estimate an equal weighted
treatment effect (−β), and a standard logistic regression model with intercept, treatment
effect, dose effect and treatment by dose interaction which was used to estimate a dose-
weighted treatment effect (−β −Φ/3). In addition, empirical Type I error estimates were
determined for Wald test statistics (QW) from standard conditional logistic regression (CLR)
models with eligible dose as a stratification variable. For the other 42 combined scenarios
with varying β, γ, and Φ, empirical power was determined similarly.
Results
Simulations
Results of the simulations are shown in panel plots in Figures 2–4 with the proportion of p-
values less than or equal to 0.05 on the vertical axis and the effect size (β) on the horizontal
axis. Empirical Type I error (size), which corresponds to effect size of zero on the horizontal
axis, is shown in each graph; by definition there is no dose effect for this scenario so the
dose effects start at effect size of 0.1. All the methods show correct size (Type I error) with
EMH 0.043, DWAEMH 0.049, Wald tests from logistic models 0.037 in the misspecified
model, 0.037 in the equal weighted treatment model and 0.047 in the dose weighted
interaction model, and Wald tests from CLR 0.037 in the equal weighted treatment model
and 0.041 in the dose weighted interaction model; all Type I error estimates had standard
errors of 0.0041 to 0.0047. Figures 2–4 illustrate the results with all 6 panels graphing the
same Type I error (size) results and the same no dose effect power results as compared to
power for the different dose and treatment by dose combinations. In Figures 2–4, the no
dose effect (i.e. α=γ=Φ=0) power results are shown as dashed lines with open circle
symbols, the dose effect (γ≠0, with or without treatment by dose interaction) power results
are shown as solid lines with closed circle symbols, the dose effect with dose weight (γ≠0,
with or without treatment by dose interaction) power results are shown as dotted lines with
open circles, EMH results are shown in red, DWAEMH results shown in blue, Wald results
shown in green, and conditional logistic regression results shown in gold. In Figure 2
showing (γ, Φ) values of (0.25, 0) and (0.50, 0), the Wald tests and EMH power curves are
very similar when a dose effect with no interaction exists and when no dose effect exists;
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while the blue DWAEMH curves (with or without a dose effect) show lower power. In
Figure 3 with (γ, Φ) values of (0.50, 0.25) and (0.75, 0.25), DWAEMH with a treatment by
dose effect (solid blue line) and EMH with no dose effect (dashed red line) show the highest
power. Figure 4 with (γ, Φ) values of (0.25, 0.25) and (0.50, 0.50), shows a gap between the
curve for DWAEMH with a treatment by dose effect (solid blue line) and the Wald (solid
green line) and EMH curves with dose effect (solid red line); the Wald with a dose effect
(short-dashed green line) and Wald from CLR (short-dashed gold- line) with a dose effect
had lower power. These results show the weighted methods have increased power as the
treatment by dose interaction (Φ) increases.
Example Trial
At the end of the trial, 278 participants who would have been assigned to 1, 2, or 3 active
FV applications if assigned to the 4FV group had evaluable follow-up data with dfs counts
ranging from 0 to 15. (Two participants who would have been assigned to 0 active FV were
excluded from these analyses.) The 0FV group had 42% with caries by two years, the 2FV
group had 25%, and the 4FV group had 16% 2 year caries incidence; more detail is shown in
Table 2.
Table 3 displays the results of nonparametric tests. Based on center strata, with binary dfs>0
(incidence), QEMH=14.5, p=0.0001, while based on the 6 cross-classified strata of center and
dose strata with dose weights QDWAEMH=14.4, p=0.0002. For categorized dfs (72% 0, 11%
1, 10% 2–4, 8% 5–15), center-stratified integer score nonparametric QEMH=13.1, p=0.0003,
while center by dose strata with dose weights QDWAEMH=12.4, p=0.0004. Additionally, for
the 3-level ordinal outcome of no caries by 2 years, caries at 2 years and caries at 1 year
with integer scores and center stratification (data shown in Table 2) had QEMH=11.9,
p=0.0006, while center by dose strata with dose weights QDWAEMH=11.34, p=0.0008.
Center by dose interaction was not statistically significant. For comparison (Table 4), from
standard logistic regression with only an indicator for center and a linear treatment effect
(0,1,2), the 1 df equal weight Wald test QW=14.0, p=0.0002, while from the model with
interaction the dose-weighted Wald test QW=12.8, p=0.0004. The corresponding standard
conditional logistic regression model, with a linear treatment effect and linear treatment by
dose effect stratifying on the 6 cross-classified strata of center and the eligible dosing
(number of active FV applications if assigned to the 4FV group), showed the interaction to
be non-significant (p=0.5488); dropping the interaction produced a 1 df conditional equal
weight contrast Wald test of 14.0 with p=0.0002; the corresponding dose weighted contrast
from standard conditional logistic regression (which included the interaction) had a Wald
test of 12.3 with p=0.0004. The equal weight contrast from standard conditional logistic
regression had an odds ratio of 0.52 (exact 95% confidence interval of 0.36–0.75). This odds
ratio indicated that one planned FV application per year reduced the odds of caries incidence
by about half and two planned FV applications per year reduced the odds of caries incidence
by almost three-quarters. Additionally, the Mantel-Cox test of the life table approach of the
data in Table 2 resulted in QEMH-MC =14.4, p=0.0001, while a dose-weighted adjusted
Mantel-Cox test stratifying each 1 year follow-up period on whether 1 or 2 active
applications would have been received if assigned to the every 6 months group resulted in
QDWAEMH-MC=12.3, p=0.0005.
Discussion
The proposed dose adjusted extended Mantel-Haenszel test (DWAEMH) shows promise as
a way to incorporate numeric or ordinal stratification factors into a nonparametric analysis.
DWAEMH, like EMH and logistic regression, provides proper size but can yield additional
power when there is a treatment by dose interaction. In confirmatory protocols, particularly
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those in regulatory environments, the statistical analysis plan should include DWAEMH as
the a priori method, or prior to beginning analysis an amendment should be filed.
The proposed DWAEMH approach has all the same limitations as EMH tests. Namely, it
assumes: row and column weights have good external justification and are chosen a priori;
row sample sizes are adequate for asymptotic properties to apply (e.g. nhi•≥5); and of course
that the treatment is assigned by a proper implementation of a valid randomization schedule
(or that the data arise from a process like stratified simple random sampling). The other
assumptions should be readily met in well conducted randomized trials. DWAEMH also
assumes there is good external justification for, and a priori specification of, stratum
weights. Weights based on a function of dose, such as log of dose, square root of dose, or
cube root of dose, would be readily justifiable; as the root increases, the weights approach
equal weighting. In this particular trial, the DWAEMH analysis assumes no order effect of
the active applications; e.g. that AAII is no different in incidence than IIAA. The
DWAEMH analysis weights the data based on dose, which may lead the reader to interpret
this as a shift from an intention-to-treat (ITT) approach toward a protocol-compliant or as-
treated approach. However, it is important to realize that the weights are based on the
eligible dosing (the number of active FV applications the participant would have received if
randomized to the 4FV group) and not the actual doses received (based on eligible dosing
and randomization), so that a separate statistic is estimated in each mutually exclusive
eligible dosing stratum and then aggregated across strata which is still in the spirit of an ITT
approach. To apply this method as an ITT approach in a regulatory setting, an amendment to
the statistical analysis plan would have to be filed before the data could be analyzed. It
would be possible to use preliminary data from other studies to perform simulations as in
this paper to characterize the sort of power gains that might be achieved without increasing
Type I error.
This stratum score approach could be utilized for Mantel-Cox time-to-event analyses in
which the strata are the usual risk sets at each time cross-classified with the dose. To
implement that approach in this example trial, the number of active doses was modified
from 1 through 3 as shown in Table 2, to 1 or 2 in each annual risk set (zeros were dropped
since they are not informative). For example, the AIII group only contributed to the 1-year
follow-up, while the IIAA group only contributed to the 2-year follow-up.
Although we expected the motivating example trial would illustrate the advantages of this
method, for this example the dose-weighted method did not show an advantage; however, it
did not show a loss in the ability to detect the effect either. This is coherent with the
simulations when there is a modest treatment by dosing interaction effect. In addition, the
example had circumstances different than usual non-adherence; instead the participants had
no conscious role in not receiving the assigned number of treatments. While unusual, there
are other circumstances which could result in a similar situation, such as a natural disaster,
break in funding, temporary institutional review board shutdown, clinic closure, or extended
staff illness, injury or turnover, which could interrupt study applications. For example, in a
recent trial in San Diego County by this same research group, wildfires interfered with study
procedures for a number of weeks. Other situations in which this DWAEMH approach
might be useful for baseline ordinal or numeric strata would include disease severity or
stage, disease correlate status (e.g. fluoride level, tobacco use, age), self-efficacy score or
internal health locus of control score, or socioeconomic status.
Finally, this paper exemplifies where a real life example motivated modifying an analytic
method. Simulations helped illustrate the properties of the method under different scenarios
to confirm it has proper Type I error and to delineate when it can perform better than
traditional methods. Interestingly when the motivating trial was completed, these data did
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not ultimately benefit from the modified method; although treatment by dosing effect
trended in the anticipated direction, enabling the weighted odds ratio estimate to indicate a
somewhat stronger treatment benefit than the unweighted estimate, the variance (on the log
odds scale) also increased, leading to somewhat less sensitivity to detect the effect per FV
application.
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Schematic of one stratum
(h=1 Clinic 1 with eligible dosing pattern AAAI)
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Empirical Power and Size for Extended Mantel-Haenszel (EMH), Dose Adjusted EMH,
Wald, and Conditional Logistic Regression (CLR) Wald Methods with No Treatment by
Eligible Dosing Interaction (Φ=0)
No Dose Effect is for the scenario with γ = Φ = 0.
Gansky et al. Page 10














Empirical Power and Size for Extended Mantel-Haenszel (EMH), Dose Adjusted EMH,
Wald, and Conditional Logistic Regression (CLR) Wald Methods with Treatment by
Eligible Dosing Interaction (Φ=0.25)
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Empirical Power and Size for Extended Mantel-Haenszel (EMH), Dose Adjusted EMH,
Wald, and Conditional Logistic Regression (CLR) Wald Methods with Simple Treatment
Effect Equal to Treatment by Eligible Dosing Interaction (γ =Φ)
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Table 1
Planned versus active applications received in example trial (N=280)
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Table 3
Caries Incidence/Increment Chi-Square Tests
Method Cross-classification Q p-Value
Extended Mantel-Haenszel center*tx*incidence 14.52 0.0001
center*dose*tx*incidence 14.16 0.0002
center*tx*increment category 13.07 0.0003
center*dose*tx*increment category 12.79 0.0003
center*tx*increment 7.88 0.0050
center*dose*tx*increment 7.63 0.0057
center*tx*ordinal caries 11.93 0.0006
center*dose*tx*ordinal caries 11.54 0.0007
Mantel-Cox (MC) center*year*tx*incidence 14.42 0.0001
Dose Weight Adjusted EMH center*dose*tx*(dose*incidence) 14.37 0.0002
center*dose*tx*(dose*increment cat) 12.40 0.0004
center*dose*tx*(dose*increment) 9.13 0.0025
center*dose*tx*(dose*ordinal caries) 11.34 0.0008
Dose Weight Adjusted MC center*dose*year*tx*incidence 12.29 0.0005
Q = chi-square; tx = treatment; incidence=dfs>0; increment=dfs; increment category= dfs category of 0, 1, 2–4, 5–15; ordinal caries=caries at 1
year, caries at 2 years, no caries at 2 years
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